These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 15670251

  • 1. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
    Iloeje UH, Yuan Y, L'italien G, Mauskopf J, Holmberg SD, Moorman AC, Wood KC, Moore RD.
    HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP, Ghani AC, Rode RA, Bartley LM, Cowling BJ, da Silva B, Donnelly CA, van Sighem AI, Cameron DW, Danner SA, de Wolf F, Anderson RM.
    AIDS; 2006 Oct 03; 20(15):1941-50. PubMed ID: 16988515
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, DAD study group.
    AIDS; 2003 May 23; 17(8):1179-93. PubMed ID: 12819520
    [Abstract] [Full Text] [Related]

  • 4. Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort.
    Vaughn G, Detels R.
    AIDS Care; 2007 Apr 23; 19(4):492-9. PubMed ID: 17453589
    [Abstract] [Full Text] [Related]

  • 5. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ.
    HIV Med; 2005 Nov 23; 6(6):396-402. PubMed ID: 16268821
    [Abstract] [Full Text] [Related]

  • 6. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG.
    Clin Infect Dis; 2005 Nov 01; 41(9):1326-32. PubMed ID: 16206110
    [Abstract] [Full Text] [Related]

  • 7. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.
    Int J Antimicrob Agents; 2005 Jul 01; 26(1):88-91. PubMed ID: 15878262
    [Abstract] [Full Text] [Related]

  • 8. Increased risk of abdominal wall hernia associated with combination anti-retroviral therapy in HIV-infected patients-results from a Swedish cohort-study.
    Sundström A, Mortimer O, Akerlund B, Karlsson A, Flamholc L, Håkangård C, Granholm H, Persson I, Morfeldt L.
    Pharmacoepidemiol Drug Saf; 2010 May 01; 19(5):465-73. PubMed ID: 20186997
    [Abstract] [Full Text] [Related]

  • 9. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F.
    Clin Ther; 2007 Jul 01; 29(7):1448-55. PubMed ID: 17825696
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group.
    Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947
    [Abstract] [Full Text] [Related]

  • 11. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A, Collaborative Group for Clinical Use of HIV Genotype Resistance Test.
    Antivir Ther; 2006 Jun 01; 11(5):553-60. PubMed ID: 16964822
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
    Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.
    HIV Med; 2007 Mar 01; 8(2):80-5. PubMed ID: 17352763
    [Abstract] [Full Text] [Related]

  • 15. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
    Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R, Swiss HIV Cohort Study.
    Clin Infect Dis; 2007 Jul 01; 45(1):111-9. PubMed ID: 17554711
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.